These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 37108147)

  • 41. Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study.
    Wong C; Chu P; Teoh J; Chiu P; Yee CH; Chau L; Chan M; Wan H; Leung S; Ng CF
    Int Urol Nephrol; 2022 May; 54(5):993-1000. PubMed ID: 35217907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
    Shah NJ; Patel VG; Zhong X; Pina L; Hawley JE; Lin E; Gartrell BA; Febles VA; Wise DR; Qin Q; Mellgard G; Joshi H; Nauseef JT; Green DA; Vlachostergios PJ; Kwon DH; Huang F; Liaw B; Tagawa S; Kantoff P; Morris MJ; Oh WK
    JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35657341
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies.
    Zapatero A; González San Segundo C; Boladeras A; Gómez Caamaño A; López Torrecilla J; Maldonado X
    Clin Transl Oncol; 2015 Mar; 17(3):223-9. PubMed ID: 25183050
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy.
    Lassemillante AC; Doi SA; Hooper JD; Prins JB; Wright OR
    Endocrine; 2015 Nov; 50(2):344-54. PubMed ID: 25636442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer.
    Gheorghe GS; Hodorogea AS; Ciobanu A; Nanea IT; Gheorghe ACD
    Curr Oncol; 2021 Aug; 28(5):3331-3346. PubMed ID: 34590590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer.
    Masuda H; Fujimoto A; Kanesaka M; Hou K; Suyama T; Araki K; Kojima S; Naya Y
    Anticancer Res; 2021 Sep; 41(9):4443-4446. PubMed ID: 34475067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
    Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
    J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
    Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer.
    Foulkes SJ; Daly RM; Fraser SF
    Endocr Relat Cancer; 2017 Mar; 24(3):R35-R48. PubMed ID: 28062546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
    Miller K
    Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk.
    Melloni C; Nelson A
    J Cardiovasc Transl Res; 2020 Jun; 13(3):451-462. PubMed ID: 31833002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate cancer: cardiovascular mortality and androgen deprivation.
    Basaria S
    Nat Rev Urol; 2009 May; 6(5):252-3. PubMed ID: 19424172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
    Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
    Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Naito S
    Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
    Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy.
    Masuda H
    Anticancer Res; 2023 Jan; 43(1):305-309. PubMed ID: 36585176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term.
    Wilcox C; Kautto A; Steigler A; Denham JW
    Oncology; 2012; 82(1):56-8. PubMed ID: 22310055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Crawley D; Adolfsson J; Rudman S; Van Hemelrijck M
    PLoS One; 2015; 10(3):e0117344. PubMed ID: 25794005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.